Skip to main content
ANRO logo

Alto Neuroscience, Inc.

ANRONYSEHealthcareBiotechnology

$22.11Today:- (-)1Y +98.57%

As of Oct 26, 2026 close

Market cap
$946.60M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$9.73$37.48
Volume (live)
-
Avg. volume (3M)
670.54K

Alto Neuroscience (ANRO) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Alto Neuroscience used $51.77M of cash in operating activities and spent $24.00K on capital expenditures. That left free cash flow of −$51.79M. It repurchased $167.00K of its own shares.

Alto Neuroscience Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Alto Neuroscience, Inc. (ANRO) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-63.24-61.43-36.31-27.71-9.19
Depreciation & Amortization0.660.500.370.340.15
Stock Based Compensation8.117.632.891.760.23
Change in Working Capital0.034.06-0.704.58-0.57
Change in Accounts Receivable0.000.000.331.16-1.29
Change in Accounts Payable0.220.52-0.631.010.46
Change in Other Working Capital0.10-0.460.15-0.060.02
Other Operating Activities2.671.810.150.630.02
Net Cash from Operating Activities-51.77-47.42-33.45-20.39-9.26
Investing Activities
Capital Expenditures-0.02-2.08-0.47-0.73-0.68
Net Cash from Investing Activities-0.02-2.08-0.47-0.73-0.68
Financing Activities
Debt Repayment-10.211.250.009.830.00
Common Stock Issued50.70137.770.180.040.01
Common Stock Repurchased-0.170.000.000.000.00
Other Financing Activities-0.85-3.33-2.05-0.34-0.21
Net Cash from Financing Activities60.08135.6968.1343.7931.69
Summary
Effect of Forex Changes on Cash-0.03-0.01-0.01-0.02-0.05
Net Change in Cash8.2686.1834.2022.6421.75
Cash at Beginning of Period168.7382.5548.3425.714.01
Cash at End of Period176.98168.7382.5548.3425.71
Free Cash Flow-51.79-49.50-33.92-21.13-9.94
Supplemental Disclosures
Interest Paid-1.000.91--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Alto Neuroscience Cash Flow

What is Alto Neuroscience's free cash flow?

Alto Neuroscience had negative free cash flow of $51.79M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$51.77M minus $24.00K of capital expenditures.

How much does Alto Neuroscience spend on capital expenditures?

Alto Neuroscience spent $24.00K on capital expenditures in fiscal 2025, compared with $2.08M a year earlier.

Does Alto Neuroscience pay dividends or buy back shares?

Yes. In fiscal 2025 Alto Neuroscience returned $167.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition